Protocol Ledger

NCT04094662 · Phase III · COMPLETED

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Interventional Phase III clinical trial protocol NCT04094662 sponsored by Daiichi Sankyo in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-18 Enrollment: 393 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04094662
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)393 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04094662
Protocol FieldVerified Registry Value
NCT IdentifierNCT04094662
Consolidated Lead SponsorDaiichi Sankyo
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment393 participants (ACTUAL)
Registered Start Date2019-09-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04094662
Hospital Research SiteLocationSite Profile
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->
Beijing Friendship Hospital , Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
Xuanwu Hospital Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI